

Literatura ACTA MEDICINAE Speciál 2017 Karcinom prsu

- 2 **Epidemiologie karcinomu prsu**
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 2 **Prediktivní vyšetření karcinomu prsu – role patologa v roce 2017**
prof. MUDr. Aleš Ryška, Ph.D. Fingerlandův ústav patologie LF UK a FN Hradec Králové
- 2 **Současné možnosti chirurgické léčby karcinomu prsu**
MUDr. Lucie Zárubová Chirurgická klinika a Klinika plastické chirurgie 3. LF UK a FN Královské Vinohrady, Praha
- 3 **Odložená rekonstrukce prsu po mastektomii**
doc. MUDr. Ondřej Měšťák, Ph.D. Klinika plastické chirurgie 1. LF UK, Nemocnice Bulovka, Praha
- 3 **Aktuality radioterapie časného karcinomu prsu**
doc. MUDr. Renata Soumarová, Ph.D. Komplexní onkologické centrum Nemocnice Nový Jičín, a. s.
- 3 **Léčba karcinomu prsu**
prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň
- 4 **Karcinom prsu u mladých žen**
MUDr. Zuzana Bielčíková Onkologická klinika 1. LF UK a VFN, Praha
- 5 **Terapie karcinomu prsu u starších pacientek**
MUDr. Tomáš Svoboda, Ph.D. Onkologická a radioterapeutická klinika KOC FN, Plzeň
- 5 **Adjuvantní a neoadjuvantní léčba časného HER pozitivního karcinomu prsu**
MUDr. Eugen Kubala Klinika onkologie a radioterapie FN Hradec Králové
- 5 **Systémová léčba pokročilého HER2 pozitivního karcinomu prsu**
MUDr. Marián Fedor, Ph.D. | MUDr. Denisa Vításková | prof. MUDr. Bohuslav Melichar, Ph.D.
Onkologická klinika LF Univerzity Palackého a Fakultní nemocnice Olomouc
- 6 **Adjuvantní terapie u pacientek s časným SR pozitivním, HER2 negativním karcinomem prsu**
MUDr. Markéta Palácová Klinika komplexní onkologické péče, MOÚ, Brno
- 6 **Aktuální možnosti léčby SR pozitivního a HER2 negativního metastatického karcinomu prsu**
MUDr. Miloš Holánek | MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče, MOÚ Brno
- 7 **Současný pohled na časný triple negativní karcinom prsu**
MUDr. Iveta Kolářová, Ph.D. Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o.,
Fakulta zdravotnických studií UP, Pardubice, Nemocnice Pardubického kraje, a. s., Pardubická nemocnice
doc. MUDr. Jaroslav Vaňásek, CSc. Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o., Fakulta
zdravotnických studií UP, Pardubice, Nemocnice Pardubického kraje, a. s., Pardubická nemocnice, UO FVZ, Hradec Králové
MUDr. Aleš Hlávka Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o., Nemocnice Pardubického kraje,
a. s., Pardubická nemocnice, UO FVZ, Hradec Králové
- 7 **Pokročilý triple negativní karcinom prsu**
MUDr. Zuzana Bielčíková | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha

Epidemiologie karcinomu prsu

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 Mužík, J. – Šnajdrová, L. – Gregor, J.: Epidemiologie karcinomu prsu v České republice. Dostupné z: <http://www.mamo.cz/index.php?pg=pro-lekare-epidemiologie-karcinomu-prsu>, aktualizace 17. 3. 2017, vyhledáno 31. 7. 2017.
- 2 Dušek, L. – Mužík, J. – Kubásek, M., et al.: *Epidemiologie zhoubných nádorů v České republice* [online]. Masarykova univerzita, Brno 2005. Dostupné z: <http://www.svod.cz>, vyhledáno 31. 7. 2017.
- 3 Katz, J.: Breast Cancer Risk Factors. Dostupné z: <http://emedicine.medscape.com/article/1945957-overview>, publikováno online 19. 12. 2016, vyhledáno 31. 7. 2017.
- 4 PDQ Screening and Prevention Editorial Board. Breast Cancer Prevention (PDQ®) Health Professional Version. Dostupné z: <https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032634/>, publikováno online 6. 4. 2017, vyhledáno 31. 7. 2017.
- 5 Parise, C. A. – Caggiano, V.: Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities. *Breast Cancer Res Treat*, 2017, 163, s. 151–158.
- 6 Ma, H. – Ursin, G. – Xu, X., et al.: Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. *Breast Cancer Res*, 2017, 19, s. 6.
- 7 Li, H. – Sun, X. – Miller, E., et al.: BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis. *J Epidemiol*, 2017, 27, s. 143–151.
- 8 Ellingjord-Dale, M. – Vos, L. – Tretli, S., et al.: Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. *Breast Cancer Res*, 2017, 19, s. 10.
- 9 Phipps, A. I. – Chlebowski, R. T. – Prentice, R., et al.: Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. *J Natl Cancer Inst*, 2011, 103, s. 470–477.
- 10 Phipps, A. I. – Chlebowski, R. T. – Prentice, R., et al.: Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2011, 20, s. 454–463.

Prediktivní vyšetření karcinomu prsu – role patologa v roce 2017

prof. MUDr. Aleš Ryška, Ph.D. Fingerlandův ústav patologie LF UK a FN Hradec Králové

- 1 Adams, A. L. – Eltoum, I. – Krontiras, H., et al.: The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. *Breast J*, 2008, 14, s. 141–146.
- 2 Al-Saleh, K. – Abd El-Aziz, N. – Ali, A., et al.: Predictive and prognostic significance of CD8(+) tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. *Oncol Lett*, 2017, 14, s. 337–344.
- 3 Denkert, C. – von Minckwitz, G. – Brase, J. C., et al.: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol*, 2015, 33, s. 983–991.
- 4 Gonzalez-Angulo, A. M. – Iwamoto, T. – Liu, S., et al.: Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. *Clin Cancer Res*, 2012, 18, s. 1109–1119.
- 5 Hornychova, H. – Melichar, B. – Tomsova, M. – Mergancova, J. – Urmínska, H. – Ryska, A.: Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. *Cancer Invest*, 2008, 26, s. 1024–1031.
- 6 Lambein, K. – Van Bockstal, M. – Vandemaële, L., et al.: Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression. *Virchows Arch*, 2017, doi: 10.1007/s00428-017-2161-8, Epub před tiskem.
- 7 Lee, K. H. – Kim, E. Y. – Park, Y. L., et al.: Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer. *Tumour Biol*, 2017, 39, 1010428317710575.
- 8 Loibl, S. – von Minckwitz, G. – Schneeweiss, A., et al.: PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. *J Clin Oncol*, 2014, 32, s. 3212–3220.
- 9 Martin-Castillo, B. – Lopez-Bonet, E. – Buxó, M., et al.: Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer. *Oncotarget*, 2015, 6, s. 7104–722.
- 10 Melichar, B. – Hornychova, H. – Kalábová, H. – Bašová, H. – Mergancová, J. – Urmínska, H. – Jandík, P. – Červinka, V. – Laco, J. – Ryška, A.: Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis. *Med Oncol*, 2012, 29, s. 2577–2585.
- 11 Melichar, B. – Študentová, H. – Kalábová, H. – Vitásková, D. – Čermáková, P. – Hornychova, H. – Ryška, A.: Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. *Anticancer Res*, 2014, 34, s. 1115–1125.
- 12 Parinyanitikul, N. – Lei, X. – Chavez-MacGregor, M., et al.: Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. *Clin Breast Cancer*, 2015, 15, s. 153–160.
- 13 Pinder, S. E. – Rakha, E. A. – Purdie, C. A., et al.: Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. *Histopathology*, 14. 1. 2015, doi: 10.1111/his.12649.
- 14 Rosa, M. – Khazai, L.: Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period. *Breast J*, 13. 7. 2017, doi: 10.1111/tbj.12858, Epub před tiskem.
- 15 Sueta, A. – Yamamoto, Y. – Yamamoto-Ibusuki, M., et al.: An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. *PLoS One*, 2014, 9, e116054, doi: 10.1371/journal.pone.0116054.
- 16 van de Ven, S. – Smit, V. T. – Dekker, T. J., et al.: Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. *Cancer Treat Rev*, 2011, 37, s. 422–430.

Současné možnosti chirurgické léčby karcinomu prsu

MUDr. Lucie Zárubová

Chirurgická klinika a Klinika plastické chirurgie 3. LF UK a FN Královské Vinohrady, Praha

- 1 Curigliano, G. – Burstein, H. J. – Winer, D. E., et al.: De-escalating and escalating treatments for early stage breast cancer: The St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. *Ann Oncol*, 2017, mdx308, dostupné z: <https://doi.org/10.1093/annonc/mdx308>, vyhledáno 21. 6. 2017.
- 2 Fisher, B. – Anderson, S. – Bryant, J., et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med*, 2002, 347, s. 1233–1241.
- 3 Veronesi, U. – Cascinelli, N. – Mariani, L., et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med*, 2002; 347, s. 1227–1232, DOI: 0.1056/NEJMoa020989.
- 4 De La Cruz, L. – Moody, A. M. – Tappy, E. E., et al.: Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. *Ann Surg Oncol*, 2015, 22, s. 3241–3249.
- 5 Giuliano, A. E. – Hunt, K. K. – Ballman, K. V., et al.: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA*, 2011, 305, s. 569–575.

Odložená rekonstrukce prsu po mastektomii

doc. MUDr. Ondřej Měšťák, Ph.D. Klinika plastické chirurgie 1. LF UK, Nemocnice Bulovka, Praha

- 1 **Slezak, S.**: An evidence-based approach to breast reconstruction. *Plast Reconstr Surg*, 2010, 126, s. 2177–2183.
- 2 **Serletti, J. M. – Fosnot, J. – Nelson, J. A., et al.**: Breast reconstruction after breast cancer. *Plast Reconstr Surg*, 2011, 127, s. 124e–135e.
- 3 **Mestak, O. – Hromadkova, V. – Fajfrova, M., et al.**: Evaluation of oncological safety of fat grafting after breast-conserving therapy: a prospective study. *An Surg Oncol*, 2016, 23, s. 776–781, doi: 10.1245/s10434-015-4908-2, Epub 14. 10. 2015.
- 4 **Eriksen, C. – Frisell, J. – Wickman, M., et al.**: Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study. *Breast Can Res Treat*, 2011, 127, s. 439–446.
- 5 **Alderman, A. – Gutowski, K. – Ahuja, A., et al.**: Postmastectomy Expander Implant Breast Reconstruction Guideline Work Group. ASPS Clinical Practice Guideline Summary on Breast Reconstruction with Expanders and Implants. *Plast Reconstr Surg*, 2014, 134, s. 648e–655e.
- 6 **Chun, Y. S. – Sinha, I. – Turko, A., et al.**: Outcomes and patient satisfaction following breast reconstruction with bilateral pedicled TRAM flaps in 105 consecutive patients. *Plast Reconstr Surg*, 2009, 125, s. 1–9.
- 7 **Nelson, J. A. – Guo, Y. – Sonnad, S. S., et al.**: Comparison between DIEP and muscle-sparing free TRAM flaps in breast reconstruction: a single surgeon's recent experience. *Plast Reconstr Surg*, 2010, 126, s. 1428–1435.
- 8 **Mestak, O. – Sukop, A. – Hsueh, Y-S., et al.**: Centrifugation versus PureGraft for fatgrafting to the breast after breast-conserving therapy. *World J Surg Oncol*, 2014, 12, s. 178.
- 9 **Mestak, O. – Mestak, J. – Bohac, M., et al.**: Breast Reconstruction after a Bilateral Mastectomy Using the BRAVA Expansion System and Fat Grafting. *Plastic and Reconstructive Surgery – Global Open*, 2013, 1, s. e71.
- 10 **Mestak, O. – Zimovjanová, M.**: Breast reconstruction by autologous fat transfer. *Rozhledy v chirurgii: měsíčník Československé chirurgické společnosti*, 2012, 91, s. 373–377.

Aktuality radioterapie časného karcinomu prsu

doc. MUDr. Renata Soumarová, Ph.D. Komplexní onkologické centrum Nemocnice Nový Jičín, a. s.

- 1 Trialists' Collaborative Group (EBCTCG), **Darby, S. – McGale, P. – Correa, C., et al.**: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Early Breast Cancer Lancet*, 2011, 378, s. 1707–1716.
- 2 **Bartelink, H. – Maingon, P. – Poortmans, P., et al.**: Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. *Lancet Oncol*, 2015, 16, s. 47–56.
- 3 **Hughes, K. S. – Schnaper, L. A. – Bellon, J. R., et al.**: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. *J Clin Oncol*, 2013, 31, s. 2382–2387.
- 4 **Pötter, R. – Gnant, M. – Kwasny, W., et al.**: Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. *Int J Radiat Oncol Biol Phys*, 2007, 68, s. 334–340.
- 5 **Kunkler, I. H. – Williams, L. J. – Jack, W. J., et al.**: PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *Lancet Oncol*, 2015, 16, s. 266–273.
- 6 **Juany, X. Z. – Chen, Y. – Chen, W. J., et al.**: Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis. *Oncotarget*, 2017, 8, s. 28215–28225.
- 7 **Walker, G. A. – Kaidar-Person, O. – Kuten, A., et al.**: Radiotherapy as sole adjuvant treatment for older patients with low-risk breast cancer. *Breast*, 2012, 21, s. 629–634.
- 8 **Murphy, C. C. – Bartholomew, L. K. – Carpentier, M. Y., et al.**: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat*, 2012, 134, s. 459–478.
- 9 **Whelan, T. J. – Pignol, J. P. – Levine, M. N., et al.**: Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med*, 2010, 362, s. 513–520.
- 10 **Haviland, J. S. – Owen, J. R. – Dewar, J. A., et al.**: START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. *Lancet Oncol*, 2013, 14, s. 1086–1094.
- 11 **Brunt, A. M. – Wheatley, D. – Yarnold, J., et al.**: Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. *Radiother Oncol*, 2016, 120, s. 114–118.
- 12 **Correa, C. – Hartus, E. E. – Leopardi, M. C., et al.**: Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. *Pract Radiat Oncol*, 2017, 7, s. 73–79.
- 13 **Hickey, B. E. – Lehman, M. – Francis, D. P., et al.**: Partial breast irradiation for early breast cancer. *Cochrane Database Syst Rev*, 2016, 7, CD007077.
- 14 EBCTCG (Early Breast Cancer Trialists' Collaborative Group), **McGale, P. – Taylor, C. – Correa, C., et al.**: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet*, 2014, 383, s. 2127–2135.
- 15 **Bromham, N. – Schmidt-Hansen, M. – Astin, M., et al.**: Axillary treatment for operable primary breast cancer. *Cochrane Database Syst Rev*, 2017, 1, CD004561.
- 16 **Donker, M. – van Tienhoven, G. – Straver, M. E., et al.**: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol*, 2014, 15, s. 1303–1310.
- 17 **Giuliano, A. E. – Galoman, K. – McCall, L., et al.**: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. *Ann Surg*, 2016, 264, s. 413–420.
- 18 **Sávolt, Á. – Péley, G. – Polgár, C., et al.**: Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. *Eur J Surg Oncol*, 2017, 43, s. 672–679.
- 19 **Poortmans, P. M. – Collette, S. – Kirkove, C., et al.**: Internal mammary and medial supraclavicular irradiation in breast cancer. *N Engl J Med*, 2015, 373, s. 317–327.
- 20 **Thorsen, L. B. – Offersen, B. V. – Danø, H., et al.**: DBCG-IMN: A population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. *J Clin Oncol*, 2016, 34, s. 314–320.
- 21 NCCN Guidelines Version 2.2017.
- 22 **Boersma, L. J. – Verloop, J. – Elkhuizen, P., et al.**: Radiotherapy after primary chemotherapy (RAPCHEM): a prospective registration study. In: 10th European breast cancer conference, březen 2016, Amsterdam, abstrakt 207.
- 23 **Garg, A. K. – Buchholz, T. A.**: Influence of neoadjuvant chemotherapy and radiotherapy for breast cancer. *Ann Surg Oncol*, 2015, 22, s. 1434–1440.
- 24 **Chapman, C. H. – Jaqsi, R.**: Postmastectomy radiotherapy after neoadjuvant chemotherapy: a review of the evidence. *Oncology (Williston Park)*, 2015, 29, s. 657–666.
- 25 **Poortmans, P. M. – Arenas, M. – Livi, L.**: Over-irradiation. *Breast*, 2017, 31, s. 295–302.

Léčba karcinomu prsu

prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

- 1 **Minckwitz, G. – Procter, M. J. – Azambuja, E., et al.**: APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2017, 35, suppl., abstrakt LBA500.
- 2 **Turner, N. C. – Ro, J. – André, F., et al.**: Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med*, 2015, 373, s. 209–219.
- 3 **Finn, R. S. – Aleshin, A. – Slamon, D. J.**: Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. *Breast Cancer Res*, 2016, 18, s. 17.
- 4 **Mayer, E. – DeMichele, A. – Dubsy, P., et al.**: Abstract OT1-03-21: PAL-LAS: Palbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. *Cancer Res*, 2016, 76.
- 5 **Slamon, D. J. – Crown, J. – Lang, I., et al.**: Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2-advanced breast cancer (ABC) (PALOMA-1/TRIO-18). *J Clin Oncol*, 2015, 33, suppl. 1.
- 6 **Finn, R. – Martin, M. – Rugo, H., et al.**: PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). *J Clin Oncol*, 2016, 34.
- 7 **Turner, N. C. – Bondarenko, I., et al.**: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- 8 **Patnaik, A. – Rosen, L. S. – Tolaney, S. M., et al.**: Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. *Cancer Res*, 2014, 74, 19, suppl.
- 9 **Tolaney, S. M. – Beeram, M. – Beck, J. T., et al.**: A phase Ib study of abemaciclib with therapies for metastatic breast cancer. *J Clin Oncol*, 2015, 33, suppl. 1.
- 10 **Dickler, M. N. – Tolaney, S. M. – Rugo, H. S., et al.**: MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. *J Clin Oncol*, 2016, 34, suppl., výroční zasedání ASCO, 3.–7. 6. 2016.
- 11 **Juric, D. – Munster, P. N. – Campone, M., et al.**: Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis. *J Clin Oncol*, 2016, 34, výroční zasedání ASCO, 3.–7. 6. 2016.
- 12 **Sanchez-Martinez, C. – Gelbert, L. M. – Shannon, H., et al.**: Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. *Mol Cancer Ther*, 2011, 10, suppl. 1.
- 13 **Finn, R. S. – Crown, J. P. – Lang, I., et al.**: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*, 2015, 16, s. 25–35.
- 14 **Turner, N. C. – Ro, J. – André, F., et al.**: PALOMA3 Study Group: Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med*, 2015, 373, s. 209–219.

Karcinom prsu u mladých žen

MUDr. Zuzana Bielčíková Onkologická klinika 1. LF UK a VFN, Praha

- Brinton, L. A. – Sherman, M. E. – Carreon, J. D., et al.: Recent trends in breast cancer among younger women in the United States. *J Natl Cancer Inst*, 2008, 100, s. 1643–1648.
- Takei, H. – Iino, Y. – Horiguchi, J., et al.: Natural history of fibroadenomas based on the correlation between size and patient age. *Jpn J Clin Oncol*, 1999, 29, s. 8–10.
- Basch, E. M. – Deal, A. M. – Dueck, A. C., et al.: Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *J Clin Oncol*, 2017, 35, suppl., abstrakt LBA2.
- Phi, X.-A. – Saadatmand, S. – De Bock, G. H., et al.: Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. *Br J Cancer*, 2016, 114, s. 631–637.
- Giger, M. L. – Inciardi, M. F. – Edwards, A., et al.: Automated breast ultrasound in breast cancer screening of women with dense breasts: reader study of mammography-negative and mammography-positive cancers. *AJR Am J Roentgenol*, 2016, 206, s. 1341–1350.
- Steyerova, P. – Zimovjanova, M. – Frybova, J., et al.: Imaging breast cancer in young women – how successful are we in diagnosing tumors in the general population? *The Breast*, 2016, 29, suppl. 1, s. S19, abstrakt P062.
- Keegan, T. H. – DeRouen, M. C., et al.: Occurrence of breast cancer subtypes in adolescent and young adult women. *Breast Cancer Res*, 2012, 14, R55–10.
- Azim, H. A. – Michiels, S. – Bedard, P. L., et al.: Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. *Clin Cancer Res*, 2012, 18, s. 1341–1351.
- Gnerlich, J. L. – Deshpande, A. D. – Jeffe, D. B., et al.: Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. *J Am Coll Surg*, 2009, 208, s. 341–347.
- Cancello, G. – Maisonneuve, P. – Mazza, M., et al.: Pathological features and survival outcomes of very young patients with early breast cancer: how much is 'very young'? *Breast*, 2013, 22, s. 1046–1051.
- Beadle, B. M. – Woodward, W. A. – Middleton, L. P., et al.: The impact of pregnancy on breast cancer outcomes in women < or = 35 years. *Cancer*, 2009, 115, s. 1174–1184.
- Aziz, S. – Pervez, S. – Khan, S., et al.: Case control study of novel prognostic markers and disease outcome in pregnancy/lactation-associated breast carcinoma. *Pathol Res Pract*, 2003, 199, s. 15–21.
- Rodriguez, A. O. – Chew, H. – Cress, R., et al.: Evidence of poorer survival in pregnancy-associated breast cancer. *Obstet Gynecol*, 2008, 112, s. 71–78.
- Gnerlich, J. L. – Deshpande, A. D. – Jeffe, D. B., et al.: Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. *J Am Coll Surg*, 2009, 208, s. 341–347.
- Fredholm, H. – Eaker, S. – Frisell, J., et al.: Breast cancer in young women: poor survival despite intensive treatment. *PLoS One*, 2009, 4, s. e7695–7710.
- Cancello, G. – Maisonneuve, P. – Rotmensz, N., et al.: Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. *Ann Oncol*, 2010, 21, s. 1974–1981.
- Han, W. – Kang, S. Y.: Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. *Breast Cancer Res Treat*, 2010, 119, s. 193–200.
- Kataoka, A. – Iwamoto, T. – Tokunaga, E., et al.: Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. *Breast Cancer Res Treat*, 2016, 160, s. 163–172.
- Azim, H. – Azim, H. A.: Targeting RANKL in breast cancer: bone metastasis and beyond. *Expert Rev Anticancer Ther*, 2013, 13, s. 195–201.
- Asselin-Labat, M. L. – Vaillant, F. – Sheridan, J. M., et al.: Control of mammary stem cell function by steroid hormone signalling. *Nature*, 2010, 465, s. 798–802.
- Schedin, P.: Pregnancy-associated breast cancer and metastasis. *Nat Rev Cancer*, 2006, 6, s. 281–291.
- Lambertini, M. – Kroman, N. – Amey, L., et al.: Safety of pregnancy in patients (pts) with history of estrogen receptor positive (ER+) breast cancer (BC): Long-term follow-up analysis from a multicenter study. *J Clin Oncol*, 2017, 35, suppl., abstrakt LBA10066.
- Shinde, S. S. – Forman, M. R. – Kuerer, H. M., et al.: Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. *Cancer*, 2010, 116, s. 4933–4943.
- Redondo, C. M. – Gago-Dominguez, M. – Ponte, S. M., et al.: Breast feeding, parity and breast cancer subtypes in a Spanish cohort. *PLoS One*, 2012, 7, s. e40543.
- Li, C. I. – Beaver, E. F. – Tang, M. T., et al.: Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. *Breast Cancer Res Treat*, 2013, 137, s. 579–587.
- Kotsopoulos, J. – Lubinski, J. – Salmena, L., et al.: Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res*, 2012, 14, s. R42–10.
- Loi, S. – Sirtaine, N. – Piette, F., et al.: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol*, 2013, 31, s. 860–867.
- Loi, S. – Michiels, S. – Salgado, R., et al.: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: the FinHER trial. *Ann Oncol*, 2014, 25, s. 1544–1550.
- Adams, S. – Gray, R. J. – Demaria, S., et al.: Prognostic value of tumor-infiltrating lymphocytes in triple negative breast cancers from two phase III randomized adjuvant breast cancer trials: EOCG 2197 and EOCG 1199. *J Clin Oncol*, 2014, 32, s. 2959–2967.
- Mao, Y. – Zhang, Y., et al.: The value of tumor-infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. *PLoS One*, 2014, 9, s. e115103.
- Denkert, C. – Loibl, S. – Noske, A., et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol*, 2010, 28, s. 105–113.
- Denkert, C. – Minckwitz, G. – Brasen, J. A., et al.: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple negative primary breast cancers. *J Clin Oncol*, 2015, 33, s. 983–981.
- Dieci, M. V. – Criscitiello, C. – Goubar, A., et al.: Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*, 2014, 25, s. 611–618.
- Miyashita, M. – Sasano, H. – Tamaki, K., et al.: Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. *Breast Cancer Res*, 2015, 17, s. 124.
- Wimberly, H. – Brown, J. R. – Schaller, K., et al.: PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. *Cancer Immunol Res*, 2015, 3, s. 326–332.
- Burstein, M. D. – Tsimelzon, A. – Poage, G. M., et al.: Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clin Cancer Res*, 2015, 21, s. 1688–1698.
- Lehmann, B. D. – Jovanović, B. – Chen, X., et al.: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. *PLoS One*, 2016, 11, s. e0157368.
- Prat, A. – Pineda, E. – Adamo, P., et al.: Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*, 2015, 24, suppl. 2, s. S26–35.
- Marcoux, D.: A study on tumor infiltrating lymphocytes (TIL) and tertiary lymphoid structures (TLS) in BRCA1 and BRCA2 mutated triple negative breast cancer (TNBC). Institut Jules Bordet – Université libre de Bruxelles. Akademický rok 2015/2016.
- Young, S. R. – Pilarski, R. T. – Donenberg, T., et al.: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. *BMC Cancer*, 2009, 9, s. 86–110.
- Goodwin, P. J. – Phillips, K. A. – West, D. W., et al.: Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. *J Clin Oncol*, 2012, 30, s. 19–26.
- Rennert, G. – Bisland-Naggan, S. – Barnett-Griness, O., et al.: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. *N Engl J Med*, 2007, 357, s. 115–123.
- Huzarski, T. – Byrski, T. – Gronwald, J., et al.: Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. *J Clin Oncol*, 2013, 31, s. 3191–3196.
- von Minckwitz, G. – Schneeweiss, A. – Loibl, S., et al.: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 747–756.
- Sikov, W. M. – Berry, D. A. – Perou, C. M., et al.: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol*, 2015, 33, s. 13–21.
- Byrski, T. – Huzarski, T. – Dent, R., et al.: Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. *Breast Cancer Res Treat*, 2014, 147, s. 401–405.
- Hoover, H. C.: Breast cancer during pregnancy and lactation. *Surg Clin North Am*, 1990, 70, s. 1151–1163.
- Moore, H. C. – Foster, R. S.: Breast cancer and pregnancy. *Semin Oncol*, 2000, 27, s. 646–653.
- Rugo, H. S.: Management of breast cancer diagnosed during pregnancy. *Curr Treat Options Oncol*, 2003, 4, s. 165–173.
- Pierce, L. J. – Levin, A. M. – Rebbeck, T. R., et al.: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. *J Clin Oncol*, 2006, 24, s. 2437–2443.
- Metcalfe, K. – Gershman, S. – Ghadirian, P., et al.: Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. *BMJ*, 2014, 348, s. g226.
- Heemskerk-Gerritsen, B. A. – Rookus, M. A. – Aalfs, C. M., et al.: Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. *Int J Cancer*, 2015, 136, s. 668–677.
- Al-Ghazal, S. K. – Sully, L. – Fallowfield, L., et al.: The psychological impact of immediate rather than delayed breast reconstruction. *EJSO*, 2000, 26, s. 17–19.
- Francis, P. A. – Regan, M. M. – Fleming, G. F., et al.: Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med*, 2015, 372, s. 436–446.
- Baselga, J. – Campone, M. – Piccart, M., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*, 2012, 366, s. 520–529.
- Cristofanilli, M. – Turner, N. C. – Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- Im, S. – Chow, L. – Shao, Z., et al.: MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy. *ESMO Asia*, 2015, abstrakt, 116TIP.
- Klijn, J. G. – Beex, L. V. – Mauriac, L., et al.: Combined treatment with busferlin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. *J Natl Cancer Inst*, 2000, 92, s. 903–911.
- Klijn, J. G. – Blamey, R. W. – Boccardo, F., et al.: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. *J Clin Oncol*, 2001, 19, s. 343–353.
- Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- de Azambuja, E. – Holmes, A. P. – Piccart-Gebhart, M., et al.: Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo-ALTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. *Lancet Oncol*, 2014, 15, s. 1137–1146.
- von Minckwitz, G. – Untch, M. – Blohmer, J. U., et al.: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*, 2012, 30, s. 1796–1804.
- Piccart-Gebhart, M. J. – Holmes, A. P. – Baselga, J., et al.: First results from the phase III ALTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T → L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2014, 32, 15, suppl., abstrakt LBA4.
- Von Minckwitz, G. – Procter, M. J. – De Azambuja, E., et al.: APHINI-TY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2017, 35, suppl., abstrakt LBA500.
- Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE). ClinicalTrials.gov Identifier: NCT02308085.
- Katoka, A. – Nakashima, E. – Teruya, N., et al.: Pregnancy outcome after endocrine therapy (ET) in hormone receptor (HR)-positive young patients with breast cancer aged 35 years or younger in Japan. *The Breast*, 2016, 29, suppl., abstrakt P050.

Terapie karcinomu prsu u starších pacientek

MUDr. Tomáš Svoboda, Ph.D. Onkologická a radioterapeutická klinika KOC FN, Plzeň

- 1 von Minckwitz, G. – Schneeweiss, A. – Loibl, S., et al.: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 747–756.
- 2 Delaloge, S. – Perol, D. – Brain, E., et al.: Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: results of a multicenter national observational study. ASCO 2016, abstrakt 1013.
- 3 Munzone, E. – Colleoni, M.: Clinical overview of metronomic chemotherapy in breast cancer. *Nature Reviews Clinical Oncology*, 2015, 12, s. 11, 631–644.
- 4 Mateen, A. – Adil, A. – Maken, R. N.: Metronomic oral chemotherapy in metastatic breast cancer. *An Oncol*, 2015, 26, suppl. 9; ix31.
- 5 Perroud, H. A. – Alasino, C. M. – Rico, M. J., et al.: Objective evaluation of quality of life in patients with advanced breast cancer treated with metronomic chemotherapy. *Eur J Cancer*, 2015, 51, suppl. 3, S225.
- 6 Ohtani, S. – Fujihara, M.: Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with HER2-negative metastatic breast cancer. *An Oncol*, 2015, 26, suppl. 9, ix30.
- 7 Brems-Eskildsen, A. S. – Linnet, S. – Luczak, A., et al.: Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients? *Supportive Care in Cancer*, 2015, 23, s. 1, suppl. 1, S353.
- 8 Hortobagyi, G. – Salmon, M. – Stemmer, M. D., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*, 2016, 375, s. 1738–1748.
- 9 Hortobagyi, G. N. – Stemmer, S. M. – Burris, H. A., et al.: First-line ribociclib + letrozole for postmenopausal women with HR+, HER2-, advanced breast cancer: First results from the phase III MONALEESA-2 study. ESMO 2016, Kodaň.

Adjuvantní a neoadjuvantní léčba časného HER pozitivního karcinomu prsu

MUDr. Eugen Kubala Klinika onkologie a radioterapie FN Hradec Králové

- 1 Fisher, B. – Brown, A. – Mamounas, E., et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol*, 1997, 15, s. 2483–2493.
- 2 Slamon, D. J. – Clark, G. M. – Wong, S. G., et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2neu oncogene. *Science*, 1987, 235, s. 177–182.
- 3 Yarden, Y. – Slivkovski, M. X.: Understanding the ErbB signalling network. *Nat Rev Mol Cell Biol*, 2001, 2, s. 127–137.
- 4 Nelson, M. H. – Dolder, C. R.: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. *Ann Pharmacother*, 40, s. 261–269.
- 5 Baselga, J. – Cortez, J. – Im, S.-A., et al.: Biomarkers analyses in Cleopatra: A phase III placebo controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer. *Cancer Res*, 2012, 72, suppl., abstrakt, s. 5.
- 6 Chan, A. – Delaloge, S. – Holmes, F. A., et al.: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled double-blind trial (ExteNET). SABCS 2015, abstrakt, s. 5–02.
- 7 Baselga, J. – Perez, E. A. – Pienkowski, T., et al.: Adjuvant trastuzumab: a milestone in the treatment of HER2-positive early breast cancer. *The Oncologist*, 2006, 11, s. 4–12.
- 8 Piccart-Gebhart, M. J. – Procter, M. – Leyland-Jones, B., et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*, 2005, 353, s. 1659–1672.
- 9 Goldhirsch, A., et al.: HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Abstrakt LBA6, kongres ESMO 2012.
- 10 Goldhirsch, A. – Piccart-Gebhart, M. J. – Procter, M., et al.: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. *Cancer Res*, 2012, 72, suppl., s. 103–104. San Antonio Breast Conference 2012, abstrakt.
- 11 Slamon, D. J. – Eiermann, W. – Robert, N. J., et al.: Ten years follow-up BCIRG-006 compared to doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive patients with early breast cancer. San Antonio Breast Cancer Symposium, 2015, abstrakt s. 5–04.
- 12 Valero, V. – Forbes, J. – Pegram, M. D., et al.: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. *J Clin Oncol*, 2011, 29, s. 149–156.
- 13 von Minckwitz, G. – Loibl, S. – Schneeweiss, A., et al.: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer. GeparSixto, SABCS 2015, abstrakt, S2–04.
- 14 van Ramshorst, M. S. – van der Heijden-van der Loo, M. – Dackus, G. M. H. E., et al.: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat? SABCS 2015, abstrakt s. 6–06.
- 15 Chan, A. – Delaloge, S. – Holmes, F. A., et al.: Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). *J Clin Oncol*, 2015, 33, suppl., abstrakt 508.
- 16 Chan, A. – Delaloge, S. – Holmes, F. A., et al.: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology*, 2016, 17, s. 367–377.
- 17 Von Minckwitz, G. – Procter, M. J. – De Azambuja, E.: APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). *J Clin Oncol*, 2017, 35, suppl., abstrakt LBA500.
- 18 Fisher, B. – Brown, A. – Mamounas, E., et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol*, 1997, 15, s. 2483–2493.
- 19 Cortazar, P. – Zhang, L. – Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- 20 Cortazar, P. – Geyer, C. E. Jr. – Gianni, L., et al.: Pathological complete response in breast cancer – authors' reply. *Lancet*, 2015, 385, s. 114–115.
- 21 U.S. Food and Drug Administration: *Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval*. Publikováno v říjnu 2014.
- 22 Gianni, L. – Pienkowski, T. – Im, Y.-H., et al.: Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (NeoSphere). *Cancer Res*, 2010, 70, suppl., abstrakt s. 3–2, s. 82.
- 23 Gianni, L. – Pienkowski, T. – Im, Y.-H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet*, 2012, 13, s. 25–32.
- 24 Gianni, L. – Pienkowski, T. – Im, Y.-H., et al.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol*, 2016, 17, s. 791–800.
- 25 Gianni, L. – Pienkowski, T. – Im, Y.-H., et al.: Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). *J Clin Oncol*, 2015, 33, suppl., abstrakt 505.
- 26 Hatzis, C. – Symmans, W. F. – Zhang, Y., et al.: Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer. *Clin Cancer Res*, 2016, 22, s. 26–33.

Systemová léčba pokročilého HER2 pozitivního karcinomu prsu

MUDr. Marián Fedor, Ph.D. | MUDr. Denisa Vitásková | prof. MUDr. Bohuslav Melichar, Ph.D.

Onkologická klinika LF Univerzity Palackého a Fakultní nemocnice Olomouc

- 1 ÚZIS. Novotvary 2014 ČR. www.uzis.cz.
- 2 Fietz, T. – Tesch, H. – Rausch, J., et al.: Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – results from the prospective German TMK cohort study. *The Breast*, 2017, 34, s. 122–130.
- 3 Loibl, S. – Gianni, L.: HER2-positive breast cancer. *Lancet*, 2017, 389, s. 2415–2429.
- 4 Hudis, C. A.: Trastuzumab – mechanism of action and use in clinical practice. *N Engl J Med*, 2007, 357, s. 39–51.
- 5 Büchler, T. – Čejková, J.: Přehled biologické léčby HER2 pozitivního metastatického karcinomu prsu. *Klin Farmakol*, 2015, 29, s. 8–12.
- 6 Vitásková, D. – Melichar, B.: Pertuzumab – nová možnost v léčbě karcinomu prsu. *Remedia*, 2013, 23, s. 302–304.
- 7 Press, M. F., et al.: HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-college of american pathologists guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials. *J Clin Oncol*, 2016, 34, s. 3518–3528.
- 8 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 2001, 344, s. 783–792.
- 9 Verma, S. – Miles, D. – Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791.
- 10 Ellis, P. A. – Barrios, Ch. – Eiermann, W., et al.: Phase III, randomized study of trastuzumab emtansine (T-DM1)(+/-) pertuzumab (P) vs. trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. Výroční zasedání ASCO, 2015.
- 11 Swain, S. M. – Baselga, J. – Kim, S. B., et al.: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*, 2015, 372, s. 724–734.
- 12 Parakh, S. – Gan, H. K. – Parslow A. C., et al.: Evolution of anti-HER2 therapies for cancer treatment. *Can Treat Rev*, 2017, 59, s. 1–21.
- 13 Johnston, S. – Pippet, J. Jr. – Pivov, X., et al.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for

postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol*, 2009, 27, s. 5538.

14 **Zhu, X. – Verma, S.** Targeted therapy in HER2-positive metastatic breast cancer: a review of the literature. *Cur Oncol*, 2015, 22, suppl. 1, s. 19.

15 **André, F. – O'Regan, R. – Ozguroglu, M., et al.** Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol*, 2014, 15, s. 580–591.

16 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3); *Ann Oncol*, 2017, 28, s. 16–33.

Adjuvantní terapie u pacientek s časným SR pozitivním, HER2 negativním karcinomem prsu

MUDr. Markéta Palácová Klinika komplexní onkologické péče, MOÚ, Brno

- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*, 2005, 365, s. 1687–1717, PubMed: 15894097.
- Cuzick, J. – Sestak, I. – Baum, M., et al.** Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. *Lancet Oncol*, 2010, 11, s. 1135–1141, PubMed: 21087898.
- Regan, M. M. – Neven, P. – Giobbie-Hurder, A., et al.** Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncol*, 2011, 12, s. 1101–1108, PubMed: 22018631.
- Forbes, J. F. – Cuzick, J. – Buzdar, A., et al.** Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *Lancet Oncol*, 2008, 9, s. 45–53, PubMed: 18083636.
- Dowsett, M. – Allred, C. – Knox, J., et al.** Relationship between quantitative estrogen and progesterone receptor expression and HER2 status with recurrence in the Arimidex, Tamoxifen, Alone or in combination trial. *J Clin Oncol*, 2008, 26, s. 1059–1065.
- Early Breast Cancer Trialists' Collaborative Group, Davies, C. – Godwin, J., et al.** Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant Tamoxifen: patient-level meta-analysis of randomised trials. *Lancet*, 2011, 378, s. 771–784.
- Rydén, L. – Heibert Arnlind, M. – Vitols, S., et al.** Aromatase inhibitor alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – meta-analyses on efficacy and adverse events based on randomized clinical trials. *Breast*, 2016, 26, s. 106–114.
- Smith, I. – Yardley, D. – Burris, H., et al.** Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: Final results of the randomized phase III femara versus anastrozole clinical evaluation. *J Clin Oncol*, 2017, 35, s. 1041–1048.
- Francis, P. A. – Regan, M. M. – Fleming, G. F., et al.** Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med*, 2015, 372, s. 436–446.
- Curigliano, G. – Burnstein, H. J. – Winer, E. P., et al.** De-escalating and escalating treatments for early-stage breast cancer: the St.Gallen International Expert Consensus Conference on primary therapy of early breast cancer 2017. *An Oncol*, 2017, 28, s. 1700–1712.
- Krop, I. – Ismaila, N. – Andrea, F., et al.** Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. American Society of clinical Oncology Clinical Practice Guideline Focused update. *J Clin Oncol*, 2017, 35, s. 2838–2847.
- Sgroi, D. C. – Sestak, I. – Cuzick, J., et al.** Prediction of late distant recurrence in patients with estrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 2-gene recurrence score and IHC4 in the TransAtac study population. *Lancet Oncol*, 2013, 14, s. 1067–1076.
- Sestak, I. – Cuzick, J. – Dowsett, M., et al.** Prediction of late distant recurrence after five years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using PAM50 risk of recurrence score. *J Clin Oncol*, 2015, 33, s. 916–922.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG)** Adjuvant bisphosphonate treatment in early breast cancer: Meta-analysis of individual patient data from randomised trials. *Lancet*, 2015, 386, s. 1353–1361.
- Sukhbinder, D. T. – Fletcher, G. G. – Blanchette, P. S., et al.** Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care ontario and ASCO clinical practice guideline. *J Clin Oncol*, 2017, 35, s. 2062–2081.

Aktuální možnosti léčby SR pozitivního a HER2 negativního metastatického karcinomu prsu

MUDr. Miloš Holánek | MUDr. Katarína Petraková, Ph.D.

Klinika komplexní onkologické péče, MOÚ Brno

- Mouridsen, H., et al.** Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. *J Clin Oncology*, 2001, 19, s. 2596–2606.
- Nabholtz, J. M., et al.** Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. *J Clin Oncology*, 2000, 18, s. 3758–3767.
- Robertson, J. F. R., et al.** Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. *J Clin Oncology*, 2009, 27, s. 4530–4535.
- Robertson, J. F. R., et al.** Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. *Lancet*, 2017, 388, s. 2997–3005.
- Bergh, J., et al.** FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. *J Clin Oncology*, 2012, 30, s. 1919–1925.
- Mehta, R. S., et al.** S1-1: a phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. *Cancer Research*, 2011, 71, suppl. S1-1-S1-1.
- Baselga, J., et al.** Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *New Eng J Med*, 2012, 366, s. 520–529.
- Faching, P. A., et al.** Breast cancer treatment with everolimus and exemestane for ER+ women – results of the 2nd interim analysis of the non-interventional trial, BRAWO. *An Oncol*, 2014, 25, suppl. 4.
- Finn, R. S., et al.** The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*, 2015, 16, s. 25–35.
- Finn, R. S., et al.** Palbociclib and letrozole in advanced breast cancer. *New Eng J Med*, 2016, 375, s. 1925–1936.
- Crostonanilli, M., et al.** Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- Hortobagyi, G. N., et al.** Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *New Eng J Med*, 2016, 375, s. 1738–1748.
- Dickler, M. N., et al.** MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. *J Clin Oncol*, 2017, abstrakt, http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.510.
- Sledge, J. R. – George, W., et al.** MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*, 2017, JCO. 2017.73. 7585.

Současný pohled na časný triple negativní karcinom prsu

MUDr. Iveta Kolářová, Ph.D. Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o.,
Fakulta zdravotnických studií UP, Pardubice, Nemocnice Pardubického kraje, a. s.,
Pardubická nemocnice

doc. MUDr. Jaroslav Vaňásek, CSc. Komplexní onkologické centrum Pardubického kraje,
Multiscan, s. r. o., Fakulta zdravotnických studií UP, Pardubice,
Nemocnice Pardubického kraje, a. s., Pardubická nemocnice, UO FVZ, Hradec Králové

MUDr. Aleš Hlávka Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o., Nemocnice
Pardubického kraje, a. s.,
Pardubická nemocnice, UO FVZ, Hradec Králové

- Kohler, B. A. – Sherman, R. L. – Howlander, N., et al.: Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. *J Natl Cancer Inst*, 2015, 107, djv048.
- Dent, R. – Trudeau, M. – Pritchard, K. I., et al.: Triple-negative breast cancer: Clinical features and patterns of recurrence. *Clin Cancer Res*, 2007, 13, s. 4429–4434.
- Bosch, A. – Eroles, P. – Zaragoza, R., et al.: Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. *Cancer Treat Rev*, 2010, 36, s. 206–215.
- de Ruijter, T. C. – Veeck, J. – de Hoon, J. P., et al.: Characteristics of triple-negative breast cancer. *J Cancer Res Clin Oncol*, 2011, 137, s. 183–192.
- Cortazar, P. – Zhang, L. – Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- Heitz, F. – Harter, P. – Lueck, H. J., et al.: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. *Eur J Cancer*, 2009, 45, s. 2792–2798.
- Lin, N. U. – Claus, E. – Sohl, J., et al.: Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. *Cancer*, 2008, 113, s. 2638–2645.
- Cadoo, K. A. – McArdle, O. – O’Shea, A. M., et al.: Management of unusual histological types of breast cancer. *Oncologist*, 2012, 17, s. 1135–1145.
- Huober, J. – Gelber, S. – Goldhirsch, A., et al.: Prognosis of medullary breast cancer: Analysis of 13 international breast cancer study group (IBCSG) trials. *Ann Oncol*, 2012, 23, s. 2843–2851.
- Petráková, K.: Triple negativní karcinom prsu: adjuvantní a neoadjuvantní léčba. Postgraduální medicína. *Novinky v onkologii*, 2016, 18, s. 118–121.
- Lehmann, B. D. – Jovanović, B. – Chen, X., et al.: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. *PLoS One*, 2016, 11, e0157368.
- Nielsen, T. O. – Hsu, F. D. – Jensen, K., et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res*, 2004, 10, s. 5367.
- Troester, M. A. – Herschkowitz, J. I. – Oh, D. S., et al.: Gene expression patterns associated with p53 status in breast cancer. *BMC Cancer*, 2006, 6, s. 276.
- Fisher, B. – Anderson, S. – Redmond, C. K., et al.: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med*, 1995, 333, s. 1456–1461.
- van Maaren, M. C. – de Munck, L. – de Bock, G. H., et al.: 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: A population-based study. *Lancet Oncol*, 2016, 17, s. 1158–1170.
- Abdulkarim, B. S. – Cuartero, J. – Hanson, J., et al.: Increased risk of locoregional recurrence for women with T1–2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. *J Clin Oncol*, 2011, 29, s. 2852–2858.
- Garcia-Etienne, C. A. – Barile, M. – Gentilini, O. D., et al.: Breast-conserving surgery in BRCA1/2 mutation carriers: Are we approaching an answer? *Ann Surg Oncol*, 2009, 16, s. 3380–3387.
- Budd, G. T. – Barlow, W. E. – Moore, H. C., et al.: SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. *J Clin Oncol*, 2015, 33, s. 58–64.
- Sparano, J. A. – Wang, M. – Martino, S., et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. *N Engl J Med*, 2008, 358, s. 1663–1671.
- Mori, H. – Kubo, M. – Nishimura, R., et al.: BRCAness as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer. *PLoS One*, 2016, <https://doi.org/10.1371/journal.pone.0167016>.
- Vaz-Luis, I. – Burstein, H. J.: Optimizing adjuvant chemotherapy and surgery for early- and late-stage breast cancer. *JAMA Oncology*, 2016, 2, s. 1399–1400.
- Chavez-MacGregor, M. – Clarke, C. A. – Lichtensztajn, D. Y., et al.: Delayed initiation of adjuvant chemotherapy among patients with breast cancer. *JAMA Oncology*, 2016, s. 322–329.
- Liedtke, C. – Mazouni, C. – Hess, K. R., et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*, 2008, 26, s. 1275.
- von Minckwitz, G. – Untch, M. – Blohmer, J. U., et al.: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*, 2012, 30, s. 1796.
- Symmans, W. F. – Peintinger, F. – Hatzis, C., et al.: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *J Clin Oncol*, 2007, 25, s. 4414–4422.
- Toi, M. – Lee, S. J. – Lee, E. S., et al.: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). 2016, abstrakt S1-07.
- Telli, M. L. – Timms, K. M. – Reid, J., et al.: Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. *Clin Cancer Res*, 2016, 22, s. 3764–3773.
- Byrski, T. – Huzarski, T. – Dent, R., et al.: Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. *Breast Cancer Res Treat*, 2014, 147, s. 401–405.
- von Minckwitz, G. – Schneeweiss, A. – Loibl, S., et al.: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 747–756.
- Sikov, W. M. – Berry, D. A. – Perou, C. M., et al.: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol*, 2014, 33, s. 13–21.
- Gadi V. K. – Davidson, N. E.: Practical approach to triple-negative breast cancer. *J Oncol Practice*, 2017, 13, s. 5, s. 293–300.
- van de Vijver, M. J. – He, Y. D. – van’t Veer, L. J., et al.: A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med*, 2002, 347, s. 1999–2009.
- Baselga, J. – Gómez, P. – Greil, R., et al.: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. *J Clin Oncol*, 2013, 31, s. 2586–2592.
- Barker, A. D. – Sigman, C. C. – Kelloff, G. J., et al.: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. *Clin Pharm Ther*, 2009, 86, s. 97–100.
- Stephens, P. J. – McBride, D. J. – Lin, M. L., et al.: Complex landscapes of somatic rearrangement in human breast cancer genomes. *Nature*, 2009, 462, s. 1005.
- Schumacher, T. N. – Schreiber, R. D.: Neoantigens in cancer immunotherapy. *Science*, 2015, 348, s. 69–74.
- Nanda, R. – Chow, L. Q. – Dees, E. C., et al.: Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. *J Clin Oncol*, 2016, 34, s. 2460–2467.
- Starodub, A. N. – Ocean, A. J. – Shah, M. A., et al.: First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. *Clin Cancer Research*, 2015, 21, s. 3870–3878.
- Yardley, D. A. – Weaver, R. – Melisko, M. E., et al.: EMERGE: A randomized phase II study of the antibody-drug conjugate glemtuzumab vedotin in advanced glycoprotein NMB-expressing breast cancer. *J Clin Oncol*, 2015, 33, s. 1609–1619.

Pokročilý triple negativní karcinom prsu

MUDr. Zuzana Bielčíková | prof. MUDr. Luboš Petruželka, CSc.

Onkologická klinika 1. LF UK a VFN, Praha

- Hammond, M. E. – Hayes, D. F. – Dowsett, M., et al.: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol*, 2010, 28, s. 2784–2795.
- Brenton, J. D. – Carey, L. A. – Ahmed, A. A., et al.: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? *J Clin Oncol*, 2005, 23, s. 7350–7360.
- Perou, C. M. – Sørlie, T. – Eisen, M. B., et al.: Molecular portraits of human breast tumours. *Nature*, 2000, 406, s. 747–752.
- Bauer, K. R. – Brown, M. – Cress, R. D., et al.: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer*, 2007, 109, s. 1721–1728.
- Howlander, N. – Altekruse, S. F. – Li, C. I., et al.: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. *J Natl Cancer Inst*, 2014, 106, dju055.
- Sajid, M. T. – Ahmed, M. – Azhar, M., et al.: Age-related frequency of triple negative breast cancer in women. *J Coll Physicians Surg Pak*, 2014, 24, s. 400–403.
- Foulkes, W. D. – Smith, I. E. – Reis-Filho, J. S.: Triple-negative breast cancer. *N Engl J Med*, 2010, 363, s. 1938–1948.
- Liedtke, C. – Mazouni, C. – Hess, K. R., et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*, 2008, 26, s. 1275–1281.
- Dent, R. – Trudeau, M. – Pritchard, K. I., et al.: Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*, 2007, 13, s. 4429–4434.
- Carey, L. A., et al.: Race, breast cancer subtypes, and survival in the

- Carolina Breast Cancer Study. *J Am Med Assoc*, 2006, 295, s. 2492–2502.
- 11 **Stoppa-Lyonnet, D. – Ansker, Y. – Dreyfus, H., et al.**: Familial invasive breast cancers: worse outcome related to BRCA 1 mutations. *J Clin Oncol*, 2000, 18, s. 4053–4059.
 - 12 The cancer genome atlas network. *Nature*, 2012, 490, s. 61–70.
 - 13 **Sortie, T. – Perou, C. M. – Tibshirani, R., et al.**: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A*, 2001, 98, s. 10869–10874.
 - 14 **Foulkes, W. D. – Brunet, J. S. – Stefansson, I. M., et al.**: The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. *Cancer Res*, 2004, 64, s. 830–835.
 - 15 **Lehmann, B. D. – Bauer, J. A. – Chen, X., et al.**: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*, 2011, 121, s. 2750–2767.
 - 16 **Lehmann, B. D. – Jovanović, B. – Chen, X., et al.**: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. *PLoS One*, 2016, 11, s. e0157368.
 - 17 **Burstein, M. D. – Tsimelzon, A. – Poage, G. M., et al.**: Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clin Cancer Res*, 2015, 21, s. 1688–1698.
 - 18 **Loi, S. – Sirtaine, N. – Piette, F., et al.**: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol*, 2013, 31, s. 860–867.
 - 19 **Adams, S. – Gray, R. J. – Demaria, S., et al.**: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol*, 2014, 32, s. 2959–2966.
 - 20 **Miller, K. – Wang, M. – Gralow, J., et al.**: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med*, 2007, 357, s. 2666–2676.
 - 21 **Miles, D. W. – Chan, A. – Dirix, L. Y., et al.**: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol*, 2010, 28, s. 3239–3247.
 - 22 **Robert, N. J. – Diéras, V. – Glaspy, J., et al.**: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. *J Clin Oncol*, 2011, 29, s. 1252–1260.
 - 23 **Baselga, J. – Gómez, P. – Greil, R., et al.**: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. *J Clin Oncol*, 2013, 31, s. 2586–2592.
 - 24 **O'Shaughnessy, J. – Schwartzberg, L. S. – Danso, M. A., et al.**: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). *J Clin Oncol*, 2011, 29, abstrakt 1007.
 - 25 **O'Shaughnessy, J. – Weckstein, D. – Vukelja, S., et al.**: Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. *Breast Cancer Res Treat*, 2007, 106, s. S32.
 - 26 **Wang, Z. – Hu, X. – Chen, L., et al.**: Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: preliminary results report of a phase II trial. *J Clin Oncol*, 2010, 28, abstrakt 1100.
 - 27 **Isakoff, S. J. – Mayer, E. L. – He, L., et al.**: TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. *J Clin Oncol*, 2015, 33, s. 1902–1909.
 - 28 **Tutt, A. – Ellis, P. – Kilburn, L., et al.**: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). *Cancer Res*, 2015, 75, abstrakt S3–01.
 - 29 **Miller, K. – Wang, M. – Gralow, J., et al.**: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med*, 2007, 357, s. 2666–2676.
 - 30 **Brodowicz, T. – Lang, I. – Kahan, Z., et al.**: Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. *Br J Cancer*, 2014, 111, s. 2051–2057.
 - 31 **Cortes, J. – O'Shaughnessy, J. – Loesch, D., et al.**: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*, 2011, 377, s. 914–923.
 - 32 **Twelves, C. H. – Cortes, J. – Vahdat, L., et al.**: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. *Breast Cancer Res Treat*, 2014, 148, s. 553–561.
 - 33 **Audeh, M. W. – Carmichael, J. – Penson, R. T., et al.**: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, 2010, 376, s. 245–251.
 - 34 **Fong, P. C. – Boss, D. S. – Yap, T. A., et al.**: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*, 2009, 361, s. 123–134.
 - 35 **Lord, Ch. J. – Ashworth, A.**: Synthetic lethality in the clinic. *Science*, 2017, 355, s. 1152–1158.
 - 36 **Robson, M. E. – Im, S.-A. – Senkus, E., et al.**: OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). *J Clin Oncol*, 2017, 35, suppl., abstrakt LBA4.
 - 37 **Han, H. S. – Dieras, V. – Robson, M., et al.**: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study. *Cancer Res*, 2017, 77, suppl., abstrakt S2–05.
 - 38 **Turner, N. C. – Tellii, M. L. – Rugo, H. S.**: Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). *J Clin Oncol*, 2017, 35, suppl., abstrakt 1007.
 - 39 **Alexandrov, L. B. – Nik-Zainal, S. – Wedge, D. C., et al.**: Signatures of mutational processes in human cancer. *Nature*, 2013, 500, s. 415–421.
 - 40 **Wang, Y. – Waters, J. – Leung, L., et al.**: Clonal evolution in breast cancer revealed by single nucleus genome sequencing. *Nature*, 2014, 512, s. 155–160.
 - 41 **Loi, S. – Michiels, S. – Salgado, R., et al.**: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol*, 2014, 25, s. 1544–1550.
 - 42 **Mittendorf, E. A. – Phillips, A. V. – Meric-Bernstam, F., et al.**: PD-L1 Expression in triple negative breast cancer. *Cancer Immunol Res*, 2014, 2, s. 361–370.
 - 43 **Rugo, H. S. – Olopade, O. I. – DeMichele, A., et al.**: I-SPY 2: Veliparib–carboplatin improves complete response rate in triple-negative breast cancer. *New Eng J Med*, 2016, 375, s. 23–34.
 - 44 **Dirix, L. – Takacs, I. – Nikolinakos, P., et al.**: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial. *Cancer Research*, 2016, 76, suppl., abstrakt S1–04.
 - 45 **Nanda, R. – Chow, L. Q. – Dees, E. C., et al.**: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. *J Clin Oncol*, 2016, 34, s. 2460–2467.
 - 46 **Adams, S. – Schmid, P. – Rugo, H. S., et al.**: A phase II clinical trial of pembrolizumab (MK-3475) as monotherapy for metastatic triple negative breast cancer (mTNBC) – (KEYNOTE-086): cohort A. *J Clin Oncol*, 2017, 15, suppl., s. 1008.
 - 47 **Rugo, H. S. – Delord, J. P. – Im, S. A., et al.**: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. *Cancer Res*, 2016, 76, suppl., abstrakt S5–7.
 - 48 **Emens, L. A. – Braithe, F. S. – Cassie, P., et al.**: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. *Cancer Res*, 2015, 75, suppl., abstrakt PD1–6.
 - 49 **Traina, T. A. – Miller, K. – Yardley, D. A., et al.**: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). *J Clin Oncol*, 2015, 33, suppl., abstrakt 1003.
 - 50 **Traina, T. A. – Yardley, D. A. – Schwartzberg, L. S., et al.**: Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0–1 prior lines of therapy. *J Clin Oncol*, 2017, 35, suppl., abstrakt 1089.
 - 51 **Gucalp, A. – Tolaney, S. – Isakoff, S. J., et al.**: Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. *Clin Cancer Res*, 2013, 19, s. 5505–5512.
 - 52 **O'Shaughnessy, J. – Campone, M. – Brain, E., et al.**: Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). *J Clin Oncol*, 2014, 32, suppl., abstrakt 519.
 - 53 **Gucalp, A. – Danso, M. A. – Elias, A. D., et al.**: Phase (Ph) 2 stage 1 clinical activity of seviterone, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01. *J Clin Oncol*, 2017, 35, suppl., abstrakt 1102.
 - 54 **Yardley, D. A. – Weaver, R. – Melisko, M. E., et al.**: EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. *J Clin Oncol*, 2015, 33, s. 1609–1619.
 - 55 **Bardia, A. – Mayer, I. A. – Diamond, J. R., et al.**: Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. *J Clin Oncol*, 2017, 35, s. 2141–2148.
 - 56 **Adams, S. – Diamond, J. – Hamilton, E., et al.**: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. *Cancer Res*, 2016, 76, suppl., abstrakt P2-11-06.